Introduction
Spermicides are biologically an obvious way of interrupting human fertility and should be convenient to use. The contribution of vaginal spermicides to contraception is becoming more widespread' but there has been a reduction in the number of products available over the past two decades.2 Advantages of spermicides include safety, availability, simplicity, convenience, and acceptability. In addition, they are appropriate for short term use or for use in conjunction with other methods. Unfortunately, however, their failure rate compared with other forms of contraception and the need to apply them shortly before intercourse limit their use and usefulness. Hence there is a need to develop novel, effective agents as spermicidal contraceptives.
Nonoxynol 9 is the active ingredient most widely used in spermicides. Chvapil et al reported liver toxicity in animals when nonoxynol 9 was injected intraperitoneally.3 Some investigators found that women who received nonoxynol 9 per vaginam for 14 days had a reduction in their serum cholesterol concentration but no changes in other values reflecting liver function. 4 In another study in women with a smaller dose of nonoxynol 9 applied per vaginam, however, these findings were disputed.5 Currently no analytical method is available to identify and quantify nonoxynol 9 in human tissues, although studies in rabbits with 14C-nonoxynol 9 indicate that it is extensively absorbed from the vagina.3
Quinine, the dextro isomer of quinidine, has long been used in Europe as a vaginal spermicide, albeit a rather ineffective one. 6 In 1973 propranolol, chlorpromazine, phenoxybenzamine, and other drugs were reported to inhibit the motility of spermatozoa in vitro.7 The property common to these drugs is membrane stabilising activity. Both the racemic dextrolaevo mixture and the dextro isomer of propranolol were shown to inhibit sperm motility.7 This suggests that the effect on sperm motility is independent of beta receptor blockade, since D-propranolol has only very weak beta receptor blocking properties. Although membrane stabilising activity has in the past been used synonymously with local anaesthetic activity, it is apparent that there is a need to redefine and separate these properties.8 The concentration of propranolol which will inhibit sperm motility by 5000, is 0-8 mmol/l (27 mg/100 ml). 9 In animals propranolol applied topically to the vagina prevented conception,' 0 and we therefore decided to evaluate the efficacy and tolerability of propranolol as a vaginal contraceptive.
Patients and methods
A total of 198 sexually active parous non-lactating women volunteers were recruited in the family planning clinic of the Hospital Sotero del Rio in Santiago. Their ages ranged from 15 to 42 years (mean 26, SD 5 6 years). All had restarted regular menstrual cycles since their last pregnancy and, having had intrauterine contraceptive devices fitted, wished to change to another form of contraception. The study continued for 11 months. Each evening from the last day of menstruation until the first day of the next mentrual period they inserted a commercially available 80 mg tablet of DL-(racemic)-propranolol into the vagina. Placement in the evening was routine whether intercourse took place in the morning or evening. No other method of contraception was used during the study.
The volunteers were reviewed after the first month of treatment and then at three monthly intervals. The pattern of menstruation, symptomatic side effects, and reasons for discontinuation were inquired for and failures documented. The data were analysed by a BDMP statistical package, which was used to calculate life table rates (survival analysis).11 In a subgroup of 30 women spinbarkeit tests were performed at between days 12 and 14 of the menstrual cycle and postcoital tests were performed on the first day that the cervical mucus was penetrable. These women were asked to insert the propranolol tablet at 9 pm and have intercourse at about 7 am on the morning of the postcoital test. The spermatozoa in the cervix were sampled and examined about three hours after intercourse.
Results
There were no noticeable effects on menstruation and no systemic adverse reactions were noted. Discontinuation because of local itching or discomfort occurred mainly in the first three months of treatment, and any such complaint was generally rated as mild. A total of 127 women years of exposure was documented (table) life table pregnancy rate at one year was 3-4/100 women and the Pearl index was 3 9/100 women years. The five women who became pregnant were not among those in whom postcoital testing was performed. All of those who became pregnant chose to terminate their pregnancy by abortion. No abnormalities were noted in the fetuses. Probably none of the women who were lost to follow up became pregnant, since they would have come to the Hospital Sotero del Rio for pregnancy testing and management. Postcoital testing did not show any motile spermatozoa in the endocervical samples.
Discussion
The expected cumulative rate of conception 12 months after removal of an intrauterine contraceptive device is 88 2/100 women. 12 Our results suggest that propranolol is an effective vaginal contraceptive whose in use failure rate compares favourably with that of other methods of contraception. It appears that sperm motility is inhibited whether intercourse occurs shortly after insertion of the tablet or is delayed for up to 10 hours. Tests detecting only immotile sperm in cervical fluids, however, may indicate that fertilisation is unlikely but not that it is impossible."3 Clinical trials typically report some complaints of discomfort and discontinuations with vaginal spermicides, but rates vary widely even for the same product. For example, only 2-6"' of Japanese users complained of irritation with Neo-Sampoon tablets compared with over 750% of Filipino women using the same product. ' In addition to the effect on sperm motility, propranolol prevents implantation in animals."' Since propranolol is extensively absorbed from the vagina,14 it is possible that its effect may be at least partly mediated by some systemic action. We suggest that further studies should be instituted to investigate the potential of this and similar compounds as vaginal contraceptives.
